PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07C 31/00 — A2

(11) International Publication Number: **WO 99/26909**

(43) International Publication Date: 3 June 1999 (03.06.99)

(21) International Application Number: PCT/IB98/02154

(22) International Filing Date: 18 November 1998 (18.11.98)

(30) Priority Data:
60/072,655 21 November 1997 (21.11.97) US

(71) Applicant *(for all designated States except US)*: PHARMACIA & UPJOHN COMPANY [US/US]; 301 Henrietta Street, Kalamazoo, MI 49001 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: WARPEHOSKI, Martha, A. [US/US]; 7600 Currylane, Portage, MI 49024 (US). MITCHELL, Mark, Allen [US/US]; 1628 Dover Road, Kalamazoo, MI 49008 (US). HARPER, Donald, E. [US/US]; 11520 Channel Drive, Plainwell, MI 49080 (US). MAGGIORA, Linda, Louise [US/US]; 4400 Glenrose Terrace, Kalamazoo, MI 49008 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
Without international search report and to be republished upon receipt of that report.

(54) Title: α–HYDROXY, –AMINO, AND HALO DERIVATIVES OF β–SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS



(I)

(57) Abstract

The present invention provides a compound of formula (I), or pharmaceutical acceptable salts thereof wherein R_1 is C_{4-12} alkyl, C_{4-12} alkenyl, C_{4-12} alkynyl, $-(CH_2)_h-C_{3-8}$ cycloalkyl, substituted and unsubstituted $-(CH_2)_h-$aryl, substituted and unsubstituted$-(CH_2)_h-$het, R_2 is substituted and unsubstituted C_{1-12} alkyl, substituted and unsubstituted C_{2-12} alkenyl, substituted and unsubstituted C_{2-12} alkynyl, substituted and unsubstituted$-(CH_2)_h-C_{3-8}$ cycloakyl, substituted and unsubstituted $-(CH_2)_h-C_{3-8}$ cycloalkenyl, substituted and unsubstituted $-(CH_2)_h-$aryl, substituted and unsubstituted $-(CH_2)_h-$heterocyclic ring, substituted and unsubstituted $-(CH_2)_i-X-R_4$ (X is –O–, $-S(=O)_j-$, $-NR_7-$, $-S(=O)_2NR_8-$, or $-C(=O)-$), and $-(CH_2)_iCHR_5R_6$. The compounds are inhibitors of matrix metalloproteinases involved in tissue degradation.